# US 2009/0270481 A1 · MODIFIED siRNA MOLECULES AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270481 A1
- Document ID: US20090270481A1
- Status: Published application
- Kind: A1
- Application number: 12/359,119
- Filed: 2009-01-23
- Published: 2009-10-29
- Earliest claimed: 2005-11-02
- Assignees: Protiva Biotherapeutics, Inc.
- Inventors: Ian MacLachlan; Adam Judge; Amy C.H. Lee; Vandana Sood
- Web page: https://patentgrep.com/patent/US20090270481A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2320/30: Special therapeutic applications
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.

## Claims

### Claim 1

A modified siRNA that silences Apolipoprotein B (ApoB) expression, wherein the modified siRNA comprises an antisense strand sequence consisting of SEQ ID NO:51.

### Claim 2 (depends on 1)

The modified siRNA of claim 1, further comprising a sense strand sequence consisting of SEQ ID NO:50.

### Claim 3 (depends on 1)

The modified siRNA of claim 1, wherein the modified siRNA is less immunostimulatory than a corresponding unmodified siRNA sequence.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a modified siRNA of claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A nucleic acid-lipid particle comprising:
(a) a modified siRNA of claim 1;
(b) a cationic lipid; and
(c) a non-cationic lipid.

### Claim 6 (depends on 5)

The nucleic acid-lipid particle of claim 5, further comprising a conjugated lipid that inhibits aggregation of particles.

### Claim 7 (depends on 6)

The nucleic acid-lipid particle of claim 6, wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate.

### Claim 8 (depends on 7)

The nucleic acid-lipid particle of claim 7, wherein the PEG-lipid conjugate comprises a PEG-dialkyloxypropyl (PEG-DAA) conjugate.

### Claim 9 (depends on 5)

The nucleic acid-lipid particle of claim 5, further comprising cholesterol.

### Claim 10 (depends on 5)

The nucleic acid-lipid particle of claim 5, wherein the modified siRNA is fully encapsulated in the nucleic acid-lipid particle.

### Claim 11 (depends on 5)

A pharmaceutical composition comprising a nucleic acid-lipid particle of claim 5 and a pharmaceutically acceptable carrier.
